HIV: primary and secondary prophylaxis for opportunistic infections

Keyphrases

• Secondary Prophylaxis 100%
• Opportunistic Infections 100%
• Primary Prophylaxis 100%
• Rifabutin 100%
• HIV Infection 66%
• Pneumocystis Jirovecii 66%
• Highly Active Antiretroviral Therapy (HAART) 66%
• People Living with HIV (PLHIV) 66%
• Cytomegalovirus 66%
• Mycobacterium Intracellulare 66%
• Ethambutol 66%
• Anti-tuberculosis 66%
• Clarithromycin 66%
• Aciclovir 66%
• Evidence Review 33%
• Inclusion Criteria 33%
• Cochrane Library 33%
• Embase 33%
• CD4 Count 33%
• MEDLINE 33%
• Herpes Simplex Virus 33%
• Clinical Evidence 33%
• U.S. Food 33%
• Itraconazole 33%
• Ganciclovir 33%
• Fungal Diseases 33%
• Macrolides 33%
• Regulatory Agencies 33%
• Opportunistic Pathogens 33%
• Varicella Zoster Virus 33%
• Trimethoprim-sulfamethoxazole (TMP-SMX) 33%
• Toxoplasmosis 33%
• Mycobacterium Avium Complex 33%
• Azithromycin 33%
• Fluconazole 33%
• Invasive Fungal Disease 33%
• Healthcare Products 33%
• Atovaquone 33%
• Famciclovir 33%

Pharmacology, Toxicology and Pharmaceutical Science

• HIV 100%
• Opportunistic Infection 100%
• Mycobacterium Avium Complex 100%
• Rifabutin 100%
• Human Immunodeficiency Virus Infection 66%
• Mycosis 66%
• Cytomegalovirus 66%
• Pneumocystis Jiroveci 66%
• Ethambutol 66%
• Clarithromycin 66%
• Diseases 66%
• Infectious Agent 33%
• Observational Study 33%
• Randomized Controlled Trial 33%
• Itraconazole 33%
• Isoniazid 33%
• Macrolide 33%
• Ganciclovir 33%
• Herpes Simplex Virus 33%
• Varicella Zoster Virus 33%
• Aciclovir 33%
• Cotrimoxazole 33%
• Azithromycin 33%
• Atovaquone 33%
• Valaciclovir 33%
• Famciclovir 33%
• Fluconazole 33%
• Toxoplasmosis 33%